









Markets
/
Stocks
/
nasdaq-slp
/

Simulations Plus Inc

SLP



View Detailed Chart

19.330USD

-0.010-0.05%

Close 12/23, 16:00（ET）Quotes delayed by 15 min

389.26MMarket Cap

LossP/E TTM



Simulations Plus Inc

19.330

-0.010-0.05%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-0.05%

5 Days

+2.49%

1 Month

+13.71%

6 Months

+13.24%

Year to Date

-30.69%

1 Year

-31.77%

View Detailed Chart

TradingKey Stock Score of Simulations Plus Inc

Currency: USD Updated: 2025-12-23

Key Insights

Simulations Plus Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Simulations Plus Inc's Score

Industry at a Glance

Industry Ranking

49 / 208

Overall Ranking

125 / 4568

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

23.000

Target Price

+17.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Simulations Plus Inc Highlights

StrengthsRisks

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.90% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 79.18M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -6.00, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 15.45M shares, decreasing 16.84% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.66K shares of this stock.